Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Brian A. Lanman Clear advanced filters

  • Treatment of KRASG12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG 510 could be effective in patients for whom treatments are currently lacking.

    • Jude Canon
    • Karen Rex
    • J. Russell Lipford
    Research
    Nature
    Volume: 575, P: 217-223

  • Reduction of systemic autoimmunity using TNF blockers may also reduce inflammatory diseases in other organs. Here, the authors use a patient database and scRNA-seq to link autoimmune diseases to benign prostatic hyperplasia (BPH), and demonstrate that prostatic hyperplasia is reduced by TNF blockers in humans and mice.

    • Renee E. Vickman
    • LaTayia Aaron-Brooks
    • Simon W. Hayward
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-15

  • A subset of patients treated with selective TRK inhibitors (including the newly approved larotrectinib) develop off-target resistance mediated by genomic acquisition of MAPK pathway-activating alterations, and may benefit from combined targeted therapy.

    • Emiliano Cocco
    • Alison M. Schram
    • Maurizio Scaltriti
    Research
    Nature Medicine
    Volume: 25, P: 1422-1427